By InvitationNot Applicable

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

Croatia50 participantsStarted 2025-04-01

Plain-language summary

The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucoma and Fuchs endothelial corneal dystrophy after cataract surgery. The main question it aims to answer is: do topical ROCK inhibitors decrease the loss of corneal endothelial cells after cataract surgery? Researchers will compare topical ROCK inhibitor to a placebo (a look-alike substance that contains no drug) Participants will: Take topical ROCK inhibitor or a placebo every day for 4 weeks after cataract surgery and visit the clinic for checkups and tests.

Who can participate

Age range40 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age between 40 and 90 years; * diagnosis of FECD and glaucoma; * cataract grade II nuclear/cortical or posterior subcapsular (Lens Opacity Classification System III \[LOCS III\]. Exclusion criteria: * other anterior segment pathology (pseudoexfoliation syndrome, corneal opacities); * ocular surface inflammation; * intraoperative complications (posterior capsular rupture, vitreous loss, IOL not implanted in the capsular bag); * previous ocular trauma or intraocular surgery

What they're measuring

Endothelial cell density (ECD)

Timeframe: 37 days

Trial details

NCT IDNCT06969586

SponsorUniversity Hospital Dubrava

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-04-01

View on ClinicalTrials.gov More Fuchs Endothelial Corneal Dystrophy trials